Avacta Group (FRA:RTQ1) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RTQ1 Avacta Group PLC FRA:RTQ1
27 GF Score
Price €0.78
GF Value €0.52
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group FFO per Share?

FFO per Share only applies to REITs.

FRA:RTQ1
27GF Score
Avacta Group PLC FRA:RTQ1
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avacta Group (FRA:RTQ1) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of €0.78 is trading 49% above its estimated GF Value™ of €0.52. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for FRA:RTQ1:

  • FFO per Share:
  • GF Value™: €0.52 vs. price of €0.78 (49% above fair value)
  • GF Score™: 27/100 with 8 warning signs

No single metric tells the full story. See the FRA:RTQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USAAVCT:UK
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
27GF Score

Get the complete analysis for FRA:RTQ1

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price
€0.52
GF Value